Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Climb 10.8% - Time to Buy?

Recursion Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • RXRX shares rose 10.8% to about $3.01 in Wednesday mid-day trading, while trading volume was 80% below its average.
  • Analysts have a consensus “Hold” rating and an average price target of $7.52; recent target changes ranged from JPMorgan’s cut to $7 to Needham’s $8 target.
  • Latest quarterly results matched the expected loss of $0.22 per share, while revenue of $18.55 million exceeded estimates of $14.81 million. The company remains unprofitable, and insiders sold 167,408 shares over the past 90 days.
  • MarketBeat previews top five stocks to own in December.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded up 10.8% during mid-day trading on Wednesday. The stock traded as high as $2.95 and last traded at $3.0130. 3,952,764 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 19,659,813 shares. The stock had previously closed at $2.72.

Analyst Ratings Changes

RXRX has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Recursion Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. Morgan Stanley lowered their price target on Recursion Pharmaceuticals from $5.90 to $5.60 and set an "equal weight" rating for the company in a report on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Needham & Company LLC restated a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Finally, JPMorgan Chase & Co. cut their target price on Recursion Pharmaceuticals from $10.00 to $7.00 and set an "overweight" rating on the stock in a research report on Monday. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $7.52.

View Our Latest Stock Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Trading Up 5.7%

The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -3.18 and a beta of 1.15. The stock's fifty day simple moving average is $3.75 and its 200-day simple moving average is $3.47.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.22). The business had revenue of $18.55 million for the quarter, compared to analyst estimates of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same quarter in the prior year, the company earned ($0.36) earnings per share. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.89 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Najat Khan sold 22,408 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director directly owned 162,156 shares of the company's stock, valued at $810,780. This represents a 13.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock valued at $701,276 in the last ninety days. Insiders own 6.65% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP raised its stake in Recursion Pharmaceuticals by 16.8% in the 3rd quarter. First Trust Advisors LP now owns 3,551,885 shares of the company's stock valued at $14,669,000 after purchasing an additional 510,056 shares during the last quarter. Jump Financial LLC lifted its position in Recursion Pharmaceuticals by 145.0% during the 3rd quarter. Jump Financial LLC now owns 2,497,200 shares of the company's stock worth $10,313,000 after acquiring an additional 1,478,027 shares in the last quarter. Bank of America Corp DE increased its position in shares of Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company's stock worth $7,665,000 after acquiring an additional 384,486 shares during the last quarter. Renaissance Technologies LLC bought a new position in Recursion Pharmaceuticals during the 1st quarter valued at $7,370,000. Finally, Bank of New York Mellon Corp grew its position in shares of Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company's stock worth $4,490,000 after acquiring an additional 331,048 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines